Neha Mehta-Shah, MD, Washington University in St Louis, St Louis, MO, discusses updated results from the Phase II TELLOMAK study (NCT03902184), looking at lacutamab alone or combined with chemotherapy for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.